about
Towards personalised therapy for von Willebrand disease: a future role for recombinant productsHuman plasma-derived FVIII/VWD concentrate (Biostate): a review of experimental and clinical pharmacokinetic, efficacy and safety dataClinical application of the PFA-100The utility of the PFA-100 in the identification of von Willebrand disease: a concise reviewUtility of the PFA-100 as a screening test of platelet function: an audit of haemostasis laboratories in Australia and New ZealandE-cigarettes and cardiovascular risk: beyond science and mysticismPrevention of venous thromboembolism: focus on mechanical prophylaxisInfluenza and cardiovascular disease: does swine-origin, 2009 H1N1 flu virus represent a risk factor, an acute trigger, or both?The diagnostic dilemma: dual presentations of clinical mucosal bleeding and venous thrombosis associated with the presence of thrombophilia markers and mild reduction in von Willebrand factor.Genetics of type 2B von Willebrand disease: "true 2B," "tricky 2B," or "not 2B." What are the modifiers of the phenotype?Thrombocytopenic platelet disorders.Paradoxical thrombosis, part 2: anticoagulant and antiplatelet therapy.Toward improved diagnosis of HIT.Clinical and laboratory diagnosis of heparin induced thrombocytopenia: an update.Laboratory testing in disseminated intravascular coagulation.C-reactive protein and venous thromboembolism: causal or casual association?Reducing errors in identification of von Willebrand disease: the experience of the royal college of pathologists of australasia quality assurance program.Von Willebrand factor collagen-binding (activity) assay in the diagnosis of von Willebrand disease: a 15-year journey.Articles from Seminars in Thrombosis & Hemostasis (STH) Archives: Part II.Development of consensus guidelines for anticardiolipin and lupus anticoagulant testing.Futility of testing for factor V LeidenImpact of experimental hypercalcemia on routine haemostasis testing.Laboratory identification of von Willebrand disease: technical and scientific perspectives.Laboratory monitoring of therapy in von Willebrand disease: efficacy of the PFA-100 and von Willebrand factor:collagen-binding activity as coupled strategies.A Review of beta2 -glycoprotein-l antibody testing results from a peer-driven multilaboratory quality assurance program.Emerging technologies and quality assurance in hemostasis: a review of findings from the Royal College of Pathologists of Australasia Quality Assurance Program.Standardization, regulation, quality assurance and emerging technologies in hemostasis: issues, controversies, benefits, and limitations.The LOC387715 polymorphism, inflammatory markers, smoking, and age-related macular degeneration. A population-based case-control study.An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult.Time to think outside the box? Proposals for a new approach to future pharmacokinetic studies of von Willebrand factor concentrates in people with von Willebrand disease.Hemostatic dysfunction associated with endocrine disorders as a major risk factor and cause of human morbidity and mortality: a comprehensive meta-review.Characterizing the Mechanistic Pathways of the Instant Blood-Mediated Inflammatory Reaction in Xenogeneic Neonatal Islet Cell TransplantationThe paradoxical relationship between serum uric acid and cardiovascular disease.Measuring the quality of journals and journal articles: the impact factor tells but a portion of the story.Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-heAir pollution and coagulation testing: a new source of biological variability?Help me, Doctor! My D-dimer is raised.Clinical features, diagnosis, and management of the antiphospholipid syndrome.A consensus approach to the formulation of guidelines for laboratory testing and reporting of antiphospholipid antibody assays.Laboratory testing and identification of antiphospholipid antibodies and the antiphospholipid syndrome: a potpourri of problems, a compilation of possible solutions.
P50
Q26748376-C20FE78B-4ACE-47DE-994F-7FDF3EC3D8B2Q26750402-FD4A2042-354C-4E4A-A246-C2A969E9F6EEQ28193589-5DEBF936-13F8-446E-9BC3-B308AA0D8E9CQ28199717-D100D330-8E3B-4E7A-8A18-EC178F88DBCAQ28213729-8E11343C-56B2-4612-A6B3-9337404672DFQ28304144-E1E5A562-69E5-4F95-8331-D4E9AF0D5393Q28308154-576C34C9-2E8F-4658-9112-A195120D8F94Q30388055-DBE6C88E-67E6-420C-8537-2C6FFF84FC15Q33378259-5F3A22C1-0975-43FE-9EA1-660C2BBE14F3Q33382459-791AD0B3-E9F6-40C9-8AA7-4138DBC9FA98Q33398347-431AA2ED-3EC9-4F3E-854F-3421E3D31F21Q33401497-D699F19A-76E9-41A4-8A76-CA50181AB976Q33424845-A82DF9CF-EBF8-41E2-A5CB-7DF6258761A5Q33441404-06E24CBD-9F5F-4F60-AFC9-9EFD412386FDQ34124887-28165F4D-4909-477D-A3C8-2AE5DE841CF2Q34130906-2D54840A-5014-49AB-A748-34BBE79E9D4BQ34550456-0AA78A3F-3097-4E8D-905B-0C3B4E262627Q34625952-5233444E-D6B8-4C9F-9958-1780BC4783EDQ35454535-2E8C9A1C-5921-465B-9FDB-6E1C52CACADDQ36038538-EC6DF701-4B90-4763-9B36-6EF20469BE8FQ36159931-601C5121-7592-451C-ACEC-527C99A876CCQ36330239-A580B24C-8A81-4542-A46C-2881BD3324C3Q36544684-8FE69241-0D20-48CC-B38B-36676E24B0E6Q36594962-04A7C1BF-9C85-4F30-9A37-C23A354F668EQ36727761-02138C24-79A4-4288-82D8-C96D77020936Q36788058-DEBB184B-AE8C-49D2-9B36-D57852B878ECQ36788084-B9373838-7C3E-425B-B83A-770430E43D57Q36922670-B1F06B50-092A-4EFF-BD92-6B84DF7D0ABEQ37050556-B6FB94EC-596C-4F79-8CB6-7624F2C2B121Q37050559-280DF5DF-0BE3-4DE8-9977-6132901789B4Q37050574-DF3A210A-B7D8-4582-8B38-BB9B24187DBFQ37097826-6FF17AA8-2598-4D45-92AE-539E22104409Q37112996-0347582A-2526-4B12-9B65-D1B134BC7702Q37130319-8C6F4339-1D9D-467C-A001-3C6BDF79FC5EQ37130356-60D041F4-EB8F-412F-91D5-5CCEF12B4303Q37189174-D0A5EB20-A63A-4183-A56A-EC4AA25C5452Q37209753-F4DAA81C-E4E0-495A-8E5B-30A1947F143AQ37249547-4F25A143-6149-4512-B7AA-1F8674C4C2F1Q37278246-456CBBCF-D930-4A2E-8017-E10AA86A72A0Q37278259-9212BA8C-42FA-410B-B87F-B29CD5CAB039
P50
name
Emmanuel J Favaloro
@ast
Emmanuel J Favaloro
@en
Emmanuel J Favaloro
@nl
type
label
Emmanuel J Favaloro
@ast
Emmanuel J Favaloro
@en
Emmanuel J Favaloro
@nl
prefLabel
Emmanuel J Favaloro
@ast
Emmanuel J Favaloro
@en
Emmanuel J Favaloro
@nl
P214
P214
P31
P7859
lccn-n2017190024